- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07197931
Comparing Advanced Ablation Techniques for Persistent Atrial Fibrillation
This clinical trial represents a significant advancement in treating persistent atrial fibrillation, a common heart rhythm disorder that affects millions worldwide. The study compares two approaches to catheter ablation - a minimally invasive procedure that uses heat or cold energy to create scar tissue in the heart to block abnormal electrical signals causing irregular heartbeats.
Understanding the Two Treatment Approaches
The research examines whether adding extra procedures beyond standard pulmonary vein isolation provides better long-term outcomes. One group receives standard circumferential pulmonary vein isolation alone, while the other receives this standard treatment plus additional mapping and ablation of triggers outside the pulmonary veins. This comparison is crucial because persistent atrial fibrillation often involves complex electrical pathways beyond just the pulmonary veins, and identifying the most effective treatment strategy could significantly improve patients' quality of life.
Comprehensive Patient Preparation and Safety
Before the procedure, all participants undergo thorough testing to ensure safety and optimal outcomes. These include:
- Transthoracic echocardiography to examine heart structure and function
- Transesophageal or intracardiac echocardiography to detect blood clots that could cause strokes
- Three-dimensional cardiac CT imaging to create detailed maps of the heart's anatomy
Medication Management
Patients receive anticoagulant therapy for one month before and at least two months after the procedure to prevent stroke and other blood clot-related complications. This is especially important since atrial fibrillation increases stroke risk. Antiarrhythmic medications may also be prescribed based on individual patient needs and physician assessment.
Detailed Study Procedures
The experimental group undergoes a more comprehensive approach:
- Standard pulmonary vein isolation is performed first
- Medication (isoproterenol) is administered to stimulate the heart and identify additional triggers
- If abnormal rhythms persist, electrical cardioversion restores normal rhythm
- Additional mapping identifies non-pulmonary vein triggers
- These extra triggers are precisely ablated
- The process is repeated to ensure all problematic areas are treated
Patient Eligibility and Safety Considerations
The study includes adults aged 19 years or older with persistent atrial fibrillation that hasn't responded well to medication and who are undergoing their first catheter ablation. Important exclusion criteria help ensure participant safety, including recent heart attacks or strokes, severe untreated heart conditions, pregnancy, and other significant health concerns that could increase procedural risks.
Measuring Success and Safety
Researchers will track outcomes over two years, focusing on:
- Recurrence of any atrial arrhythmia lasting 30 seconds or longer
- Need for additional antiarrhythmic medications
- Specific recurrence of atrial fibrillation versus atrial flutter/tachycardia
- Need for repeat cardioversion procedures
- Any procedure-related complications
The Importance of This Research
This study addresses a critical question in cardiac electrophysiology: whether more extensive ablation procedures provide meaningful benefits over standard approaches. For patients living with persistent atrial fibrillation, the findings could lead to more effective treatments with better long-term outcomes. Atrial fibrillation significantly impacts quality of life, causing symptoms like palpitations, fatigue, shortness of breath, and increased stroke risk. Finding the most effective ablation strategy could reduce symptom burden, decrease medication dependence, lower stroke risk, and improve overall quality of life for millions of patients worldwide. The research also contributes to understanding the complex nature of persistent atrial fibrillation and how different electrical triggers contribute to this condition. As catheter ablation becomes more common for treating atrial fibrillation, studies like this help refine techniques and establish evidence-based standards of care that balance effectiveness with safety.
Upcoming Clinical Trials
-
NCT07904767Not yet recruiting
-
NCT07931924Not yet recruitingUrinary Incontinence | Neurogenic Bladder | Urinary Diversion | Pelvic Malignancy | Urinary Bladder Carcinoma
-
NCT07932964RecruitingNormal Hearing | Noise Exposure | Preferred Loudness Level
-
NCT07933419Not yet recruitingClear Cell Renal Cell Carcinoma | Ovarian Cancer | Other Advanced Solid Tumors
-
NCT07931144Not yet recruitingNecrotizing Enterocolitis of Newborn | Late Onset Neonatal Sepsis
-
NCT07889232Not yet recruitingMetastatic Non-Small Cell Lung Cancer | Cancer-Associated Weight Loss | Elevated Inflammatory Markers
-
NCT07931534Not yet recruitingHypertrophy | Tonsillectomy | Airway Obstruction Upper | Adenoidectomy Surgery
-
NCT07933536Not yet recruitingModerate to Severe Psoriasis
-
NCT07930793RecruitingAplastic Anemia | Clonal Hematopoiesis | Immunosuppressive Therapy
-
NCT07933185RecruitingJaw Cysts | Alveolar Bone Defects
-
NCT07932535Not yet recruiting
-
NCT07933211Not yet recruiting